<?xml version='1.0' encoding='utf-8'?>
<document id="29150561"><sentence text="Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients."><entity charOffset="13-25" id="DDI-PubMed.29150561.s1.e0" text="Enzalutamide" /><entity charOffset="29-40" id="DDI-PubMed.29150561.s1.e1" text="Cabazitaxel" /><pair ddi="false" e1="DDI-PubMed.29150561.s1.e0" e2="DDI-PubMed.29150561.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29150561.s1.e0" e2="DDI-PubMed.29150561.s1.e1" /></sentence><sentence text="Purpose: In ongoing clinical research on metastatic castration-resistant prostate cancer (mCRPC) treatment, the potential enhanced efficacy of the combination of taxanes with AR-targeted agents, that is, enzalutamide and abiraterone, is currently being explored"><entity charOffset="162-169" id="DDI-PubMed.29150561.s2.e0" text="taxanes" /><entity charOffset="204-216" id="DDI-PubMed.29150561.s2.e1" text="enzalutamide" /><entity charOffset="221-232" id="DDI-PubMed.29150561.s2.e2" text="abiraterone" /><pair ddi="false" e1="DDI-PubMed.29150561.s2.e0" e2="DDI-PubMed.29150561.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29150561.s2.e0" e2="DDI-PubMed.29150561.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29150561.s2.e0" e2="DDI-PubMed.29150561.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29150561.s2.e1" e2="DDI-PubMed.29150561.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29150561.s2.e1" e2="DDI-PubMed.29150561.s2.e2" /></sentence><sentence text=" Because enzalutamide induces the CYP3A4 enzyme and taxanes are metabolized by this enzyme, a potential drug-drug interaction needs to be investigated"><entity charOffset="9-21" id="DDI-PubMed.29150561.s3.e0" text="enzalutamide" /><entity charOffset="52-59" id="DDI-PubMed.29150561.s3.e1" text="taxanes" /><pair ddi="false" e1="DDI-PubMed.29150561.s3.e0" e2="DDI-PubMed.29150561.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29150561.s3.e0" e2="DDI-PubMed.29150561.s3.e1" /></sentence><sentence text="Experimental Design: Therefore, we performed a pharmacokinetic cross-over study in mCRPC patients who were scheduled for treatment with cabazitaxel Q3W (25 mg/m2)"><entity charOffset="136-147" id="DDI-PubMed.29150561.s4.e0" text="cabazitaxel" /></sentence><sentence text=" Patients were studied for three consecutive cabazitaxel cycles"><entity charOffset="45-56" id="DDI-PubMed.29150561.s5.e0" text="cabazitaxel" /></sentence><sentence text=" Enzalutamide (160 mg once daily) was administered concomitantly after the first cabazitaxel cycle, during 6 weeks"><entity charOffset="1-13" id="DDI-PubMed.29150561.s6.e0" text="Enzalutamide" /><entity charOffset="81-92" id="DDI-PubMed.29150561.s6.e1" text="cabazitaxel" /><pair ddi="false" e1="DDI-PubMed.29150561.s6.e0" e2="DDI-PubMed.29150561.s6.e0" /><pair ddi="false" e1="DDI-PubMed.29150561.s6.e0" e2="DDI-PubMed.29150561.s6.e1" /></sentence><sentence text=" Primary endpoint was the difference in mean area under the curve (AUC) between the first (cabazitaxel monotherapy) and third cabazitaxel cycle, when enzalutamide was added"><entity charOffset="126-137" id="DDI-PubMed.29150561.s7.e0" text="cabazitaxel" /><entity charOffset="150-162" id="DDI-PubMed.29150561.s7.e1" text="enzalutamide" /><pair ddi="false" e1="DDI-PubMed.29150561.s7.e0" e2="DDI-PubMed.29150561.s7.e0" /><pair ddi="false" e1="DDI-PubMed.29150561.s7.e0" e2="DDI-PubMed.29150561.s7.e1" /></sentence><sentence text="Results: A potential clinically relevant 22% (95% CI, 9%-34%; P = 0"><entity charOffset="50-52" id="DDI-PubMed.29150561.s8.e0" text="CI" /></sentence><sentence text="005) reduction in cabazitaxel exposure was found with concomitant enzalutamide use"><entity charOffset="18-29" id="DDI-PubMed.29150561.s9.e0" text="cabazitaxel" /><entity charOffset="66-78" id="DDI-PubMed.29150561.s9.e1" text="enzalutamide" /><pair ddi="false" e1="DDI-PubMed.29150561.s9.e0" e2="DDI-PubMed.29150561.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29150561.s9.e0" e2="DDI-PubMed.29150561.s9.e1" /></sentence><sentence text=" The geometric mean AUC0-24h of cabazitaxel was 181 ng*h/mL (95% CI, 150-219 ng*h/mL) in cycle 3 and 234 ng*h/mL (95% CI, 209-261 ng*h/mL) in cycle 1"><entity charOffset="32-43" id="DDI-PubMed.29150561.s10.e0" text="cabazitaxel" /><entity charOffset="65-67" id="DDI-PubMed.29150561.s10.e1" text="CI" /><entity charOffset="118-120" id="DDI-PubMed.29150561.s10.e2" text="CI" /><pair ddi="false" e1="DDI-PubMed.29150561.s10.e0" e2="DDI-PubMed.29150561.s10.e0" /><pair ddi="false" e1="DDI-PubMed.29150561.s10.e0" e2="DDI-PubMed.29150561.s10.e1" /><pair ddi="false" e1="DDI-PubMed.29150561.s10.e0" e2="DDI-PubMed.29150561.s10.e2" /><pair ddi="false" e1="DDI-PubMed.29150561.s10.e1" e2="DDI-PubMed.29150561.s10.e1" /><pair ddi="false" e1="DDI-PubMed.29150561.s10.e1" e2="DDI-PubMed.29150561.s10.e2" /></sentence><sentence text=" This combination did not result in excessive toxicity, whereas PSA response was promising" /><sentence text="Conclusions: We found a significant decrease in cabazitaxel exposure when combined with enzalutamide"><entity charOffset="48-59" id="DDI-PubMed.29150561.s12.e0" text="cabazitaxel" /><entity charOffset="88-100" id="DDI-PubMed.29150561.s12.e1" text="enzalutamide" /><pair ddi="false" e1="DDI-PubMed.29150561.s12.e0" e2="DDI-PubMed.29150561.s12.e0" /><pair ddi="false" e1="DDI-PubMed.29150561.s12.e0" e2="DDI-PubMed.29150561.s12.e1" /></sentence><sentence text=" In an era of clinical trials on combination strategies for mCRPC, it is important to be aware of clinically relevant drug-drug interactions" /><sentence text=" Because recent study results support the use of a lower standard cabazitaxel dose of 20 mg/m2, the clinical relevance of this interaction may be substantial, because the addition of enzalutamide may result in subtherapeutic cabazitaxel exposure"><entity charOffset="66-77" id="DDI-PubMed.29150561.s14.e0" text="cabazitaxel" /><entity charOffset="183-195" id="DDI-PubMed.29150561.s14.e1" text="enzalutamide" /><entity charOffset="225-236" id="DDI-PubMed.29150561.s14.e2" text="cabazitaxel" /><pair ddi="false" e1="DDI-PubMed.29150561.s14.e0" e2="DDI-PubMed.29150561.s14.e0" /><pair ddi="false" e1="DDI-PubMed.29150561.s14.e0" e2="DDI-PubMed.29150561.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29150561.s14.e0" e2="DDI-PubMed.29150561.s14.e2" /><pair ddi="false" e1="DDI-PubMed.29150561.s14.e1" e2="DDI-PubMed.29150561.s14.e1" /><pair ddi="false" e1="DDI-PubMed.29150561.s14.e1" e2="DDI-PubMed.29150561.s14.e2" /></sentence><sentence text=" Clin Cancer Res; 24(3); 541-6" /><sentence text=" Â©2017 AACR" /><sentence text="" /></document>